Lisa M. Brown, M.D., M.A.S.
· Assistant Professor of SurgeryVerifiedUniversity of California, Davis · Surgery
Active 1977–2026
About
Lisa M. Brown, M.D., M.A.S., is a faculty member in the Department of Surgery at UC Davis Health, specializing in General Thoracic Surgery and Pediatric Cardiothoracic Surgery. Her role involves clinical practice, research, and education within these surgical specialties. She is part of a multidisciplinary team dedicated to advancing surgical care and research in thoracic and pediatric cardiothoracic surgery, contributing to the department's mission of providing comprehensive surgical services and fostering innovative research in these fields.
Research topics
- Medicine
- Intensive care medicine
- Internal medicine
- Psychology
- Political Science
- Surgery
- Archaeology
- Ancient history
- Geography
- Criminology
- General surgery
- Medical emergency
- Demography
- Ethnology
- Law
- Virology
- History
- Nursing
- Family medicine
- Gerontology
- Oncology
- Medical physics
Selected publications
Journal of Alzheimer s Disease · 2026-03-16
articleBackgroundDepression assessment in persons with dementia (PWD) often prioritizes caregiver report, with limited integration of self-report due to concerns about PWD insight.ObjectiveThis cross-sectional study examined discrepancies between self- and caregiver-reported depression in PWD and identified neuropsychiatric and diagnostic predictors of discordance.Methods402 PWD diagnosed with Alzheimer's disease (AD), behavioral variant frontotemporal dementia (bvFTD), semantic variant primary progressive aphasia (svPPA), or progressive supranuclear palsy (PSP) self-reported depression using the Geriatric Depression Scale (GDS), while caregivers completed the Neuropsychiatric Inventory (NPI). Discrepancies were categorized as Concordant (agreement), Discordant Type 1 (self-reported depression denied by caregiver), or Discordant Type 2 (caregiver-reported depression denied by PWD).ResultsOne-third (33.8%) of dyads showed discrepancies: 66.2% were concordant, 10.2% Discordant Type 1, and 23.6% Discordant Type 2. PSPs had higher incidence of Type 1 discordance compared to AD (OR = 2.91, p < 0.05), while svPPAs were less likely to incur Type 2 discordance than AD (OR = 0.33, p < 0.01). Higher self-reported GDS Hopelessness, Withdrawal, and Worry predicted higher rates of Type 1 discordance, while lower Dysphoria predicted Type 2 discordance. Higher caregiver-reported NPI Apathy increased odds of Type 1 discordance (OR = 2.46, p < 0.05) and lower NPI Anxiety increased odds of Type 2 discordance (OR = 0.50, p < 0.01). Among cases with Type 1 discordance, caregivers often endorsed PWD apathy, irritability, agitation, or anxiety instead of depression.ConclusionsDiscrepancies in reporting depression in PWD can reflect underreporting by caregivers, not only denial by PWD. Integrating self-report, caregiver input, and clinical judgment may improve diagnostic accuracy for depression in PWD and improve care.
Clinical patterns in social cognition & personality changes in progressive supranuclear palsy
Journal of Neurology · 2026-05-09
articlePhysiotherapy · 2025-03-28
articleThe Annals of Thoracic Surgery · 2025-01-27 · 11 citations
articleSenior authorAnnals of Thoracic Surgery Short Reports · 2025-07-30
articleOpen accessBackground: Lung cancer screening is as an effective strategy for early diagnosis in high-risk patients, with proven impact on decreasing mortality. Individuals with malignancies of the head and neck have risk factors similar to those with lung cancer, with the most notable being a shared association with current or previous smoking. We evaluated the prevalence of lung cancer screening candidacy and implementation among head and neck cancer clinic patients. Methods: Anonymous surveys were collected from patients who presented to the head and neck cancer clinic at a single, tertiary-care center from May 2024 to August 2024. Individuals were queried regarding their candidacy for and experiences with lung cancer screening. Descriptive analyses were performed. Results: A total of 202 patients were surveyed, with median age of 66 (interquartile range, 15) years. Within this cohort, 77 (38.0%) previously smoked and 15 (7.4%) currently smoked. Among all respondents, 23 (11.4%) met 2021 United States Preventative Service Taskforce criteria for lung cancer screening. Most of the patients (16 [69.6%]) who met criteria had never been offered screening. Seven patients (30.4%) who were eligible for lung cancer screening were previously offered screening and completed it. Of the 25 patients who were screened in the entire cohort, 5 (20%) were diagnosed with lung cancer. Conclusions: A substantial proportion of head and neck cancer patients are eligible for lung cancer screening. The low levels of screening highlighted in this shared patient population serve as an opportunity for quality improvement, especially given the high frequency of cancer diagnoses among those who received screening.
Human Rights Violations and Trauma
2025-01-01
book-chapterSenior authorTrauma and Stressor-Related Disorders
2025-01-01 · 1 citations
book-chapterSenior authorJournal of Thoracic Oncology · 2025-10-01
articleActive-Duty Service Members and Suicidality: Resilience and Prevention
2025-01-01
book-chapterSenior authorMolecular Cancer Therapeutics · 2025-10-22
articleAbstract Introduction: Deficiency in MGMT expression, through low gene/protein expression and/or silencing of the MGMT promoter along with a functional DNA mismatch repair pathway, significantly increases a cancer cell’s sensitivity to temozolomide (TMZ) treatment, particularly in glioblastoma. To understand whether MGMT deficiency affects response to TMZ in other cancer types, preclinical drug studies were performed in patient-derived xenograft (PDX) models selected from the NCI Patient-Derived Models Repository (PDMR: https://pdmr.cancer.gov). MGMT deficiency was measured using a CLIA-validated promoter methylation assay (PMR assay), protein expression by immunohistochemistry (IHC), and gene expression by RNAseq. Here we evaluated the concordance of MGMT status across different assays and their correlations with response to TMZ. Methods: Eighty-eight pan-cancer PDX models, including solid tumors and sarcomas, were used in TMZ preclinical studies. MGMT deficiency was determined using the following criteria: promoter methylation ratio ≥ 2 by PMR assay, low protein expression (tumor nuclear staining &lt; 30%) by IHC, or low gene expression (z-score of normalized count &lt; -1.65) by RNAseq. For each model, PDX samples from 2 passages were evaluated to assess consistency in MGMT promoter methylation and protein expression during passaging. The survival metric of relative median delay in tumor quadrupling for event-free survival (EFSx4) was used to quantify tumor growth delay of the models treated with TMZ. Results: Out of 88 models, 7 models were identified as MGMT deficient and 71 models as MGMT proficient across all three assays, resulting in an assay concordance rate of 88.64% (78/88). Among the 10 discordant models, 3 were MGMT promoter unmethylated, but showed low MGMT protein and gene expression. Conversely, 5 models were MGMT promoter methylated, but had high MGMT gene and protein expression. Possible reasons for these discrepancies include differences in sensitivity of the assays and post-transcriptional/translational regulation of MGMT gene/protein expression. One urothelial/bladder cancer model showed inconsistent IHC results and one Hurthle cell neoplasm showed inconsistent PMR results between 2 passages suggesting tumor heterogeneity within these models. Comparing the EFSx4 response metric and MGMT status, MGMT-deficient models treated with TMZ had a mean EFSx4 of 1.9, 1.8, and 2.1 when detected by PMR assay (n=13), IHC (n=10), and RNAseq (n=11), respectively. These durations were statistically significant (p&lt;0.0001, Wilcoxon rank sum test) compared with MGMT proficient models treated with TMZ (mean EFSx4 = 1.1). Conclusion: Three MGMT assays showed good concordance in TMZ preclinical studies using PDMR models. Substantial responses to TMZ suggest that this drug represents an effective treatment for patients with MGMT deficiency, regardless of cancer type. Citation Format: Li Chen, Shahanawaz Jiwani, Lindsay Dutko, Vishnu Rahul Kannan, Maria Saeed, Alyssa Chapman, Lisa Brown, Nikitha Nair, Corinne Camalier, Biswajit Das, Ting-Chia Chang, Chelsea McGlynn, Howard Stotler, Shannon Uzelac, Justine Mills, Tiffanie Chase-Miner, Cindy Timme, Yvonne Evrard, Laura Kuhlmann, Dianne Newton, Melinda Hollingshead, Chris Karlovich, Mickey Williams, James Doroshow. MGMT as a pan-cancer biomarker in temozolomide preclinical studies using models from the NCI PDMR [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2025 Oct 22-26; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2025;24(10 Suppl):Abstract nr A005.
Frequent coauthors
- 60 shared
David C. Devonis
Elms College
- 45 shared
David T. Cooke
University of California, Davis
- 35 shared
Kathryn Hyer
University of South Florida
- 33 shared
Elizabeth A. David
University of Colorado Denver
- 29 shared
Arun Hampapur
IBM Research - Thomas J. Watson Research Center
- 26 shared
John A. Schinka
University of South Florida
- 25 shared
Yingli Tian
- 24 shared
Edward White
Texas A&M University
Labs
Education
- 2002
Ph.D., Pacific Graduate School of Psychology
Palo Alto University
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Lisa M. Brown, M.D., M.A.S.
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup